Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Registration Trial of ANG-3777 for Prevention of Cardiac-Surgery Associated Acute Kidney Injury (CSA-AKI)

Next Previous
X
Search
Trial Profile

A Phase 3 Registration Trial of ANG-3777 for Prevention of Cardiac-Surgery Associated Acute Kidney Injury (CSA-AKI)

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 21 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Terevalefim (Primary)
  • Indications Acute kidney injury
  • Focus Registrational; Therapeutic Use
  • Sponsors Angion Biomedica; Elicio Therapeutics

    • Most Recent Events

    • 01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
    • 30 Apr 2021 New trial record
    • 29 Apr 2021 According to an Angion Biomedica media release, the Phase 2 prevention trial (NCT02771509) was designed to generate data on ANG-3777 in CSA-AKI patients to help guide future development of ANG-3777 in this Phase 3 registration trial for CSA-AKI. The company is planning to start the confirmatory trial early in 2022, subject to the results of the Phase 2 trial (NCT02771509) as well as discussions with the FDA and other relevant health authorities.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top